BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 25825497)

  • 41. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma.
    Yuan Y; Wang Q; Paulk J; Kubicek S; Kemp MM; Adams DJ; Shamji AF; Wagner BK; Schreiber SL
    ACS Chem Biol; 2012 Jul; 7(7):1152-7. PubMed ID: 22536950
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
    Fabini E; Manoni E; Ferroni C; Rio AD; Bartolini M
    Future Med Chem; 2019 Apr; 11(8):901-921. PubMed ID: 30998113
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells.
    Collins HM; Abdelghany MK; Messmer M; Yue B; Deeves SE; Kindle KB; Mantelingu K; Aslam A; Winkler GS; Kundu TK; Heery DM
    BMC Cancer; 2013 Jan; 13():37. PubMed ID: 23356739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and Characterizations of Novel, Selective Histone Methyltransferase SET7 Inhibitors by Scaffold Hopping- and 2D-Molecular Fingerprint-Based Similarity Search.
    Ding H; Lu WC; Hu JC; Liu YC; Zhang CH; Lian FL; Zhang NX; Meng FW; Luo C; Chen KX
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29498708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SMYD2 suppresses p53 activity to promote glucose metabolism in cervical cancer.
    Wang Y; Jin G; Guo Y; Cao Y; Niu S; Fan X; Zhang J
    Exp Cell Res; 2021 Jul; 404(2):112649. PubMed ID: 34015314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.
    Ma A; Yu W; Li F; Bleich RM; Herold JM; Butler KV; Norris JL; Korboukh V; Tripathy A; Janzen WP; Arrowsmith CH; Frye SV; Vedadi M; Brown PJ; Jin J
    J Med Chem; 2014 Aug; 57(15):6822-33. PubMed ID: 25032507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The repositioning of epigenetic probes/inhibitors identifies new anti-schistosomal lead compounds and chemotherapeutic targets.
    Whatley KCL; Padalino G; Whiteland H; Geyer KK; Hulme BJ; Chalmers IW; Forde-Thomas J; Ferla S; Brancale A; Hoffmann KF
    PLoS Negl Trop Dis; 2019 Nov; 13(11):e0007693. PubMed ID: 31730617
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
    Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
    Li LX; Fan LX; Zhou JX; Grantham JJ; Calvet JP; Sage J; Li X
    J Clin Invest; 2017 Jun; 127(7):2751-2764. PubMed ID: 28604386
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lysine methyltransferase Smyd2 regulates Hsp90-mediated protection of the sarcomeric titin springs and cardiac function.
    Voelkel T; Andresen C; Unger A; Just S; Rottbauer W; Linke WA
    Biochim Biophys Acta; 2013 Apr; 1833(4):812-22. PubMed ID: 23047121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
    Zagni C; Chiacchio U; Rescifina A
    Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.
    Sweis RF; Wang Z; Algire M; Arrowsmith CH; Brown PJ; Chiang GG; Guo J; Jakob CG; Kennedy S; Li F; Maag D; Shaw B; Soni NB; Vedadi M; Pappano WN
    ACS Med Chem Lett; 2015 Jun; 6(6):695-700. PubMed ID: 26101576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
    Chandramouli B; Chillemi G
    J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
    Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
    Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization.
    Dashti P; van de Peppel J; Thaler R; Paradise CR; Stein GS; Montecino MA; van Leeuwen JPTM; van der Eerden BJ; Dudakovic A; van Wijnen AJ
    Gene; 2023 Jan; 851():146928. PubMed ID: 36191822
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting Epigenetic Changes Mediated by Members of the SMYD Family of Lysine Methyltransferases.
    Padilla A; Manganaro JF; Huesgen L; Roess DA; Brown MA; Crans DC
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838987
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insights for the design of protein lysine methyltransferase G9a inhibitors.
    Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
    Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
    Blawski R; Vokshi BH; Guo X; Kittane S; Sallaku M; Chen W; Gjyzari M; Cheung T; Zhang Y; Simpkins C; Zhou W; Kulick A; Zhao P; Wei M; Shivashankar P; Prioleau T; Razavi P; Koche R; Rebecca VW; de Stanchina E; Castel P; Chan HM; Scaltriti M; Cocco E; Ji H; Luo M; Toska E
    Cell Rep; 2024 May; 43(5):114174. PubMed ID: 38700982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
    Liu L; Liu F; Guan Y; Zou J; Zhang C; Xiong C; Zhao TC; Bayliss G; Li X; Zhuang S
    FASEB J; 2021 Jul; 35(7):e21715. PubMed ID: 34143514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.